ReeIMCSmits-WintjensVEHJvan der BomJGvan KlinkJMMOepkesDLoprioreE. Neonatal management and outcome in alloimmune hemolytic disease. Expert Rev Hematol. 2017;10:607-616. doi:10.1080/17474086.2017.1331124
2.
MoiseKJJrArgotiPS.Management and prevention of red cell alloimmunization in pregnancy: a systematic review. Obstet Gynecol. 2012;120:1132-1139. doi:10.1097/AOG.0b013e31826d7dc1
3.
GhesquiereLGarabedianCCoulonC, et al. Management of red blood cell alloimmunization in pregnancy. J Gynecol Obstet Hum Reprod. 2018;47:197-204. doi:10.1016/j.jogoh.2018.02.001
4.
MurrayNARobertsIA.Haemolytic disease of the newborn. Arch Dis Child Fetal Neonatal Ed. 2007;92:F83-F88. doi:10.1136/adc.2005.076794
al-AlaiyanSal OmranA.Late hyporegenerative anemia in neonates with rhesus hemolytic disease. J Perinat Med. 1999;27:112-115. doi:10.1515/JPM.1999.014
7.
MillardDDGiddingSSSocolML, et al. Effects of intravascular, intrauterine transfusion on prenatal and postnatal hemolysis and erythropoiesis in severe fetal isoimmunization. J Pediatr. 1990;117:447-454. doi:10.1016/s0022-3476(05)81096-0
GiblettERVarelaJEFinchCA.Damage of the bone marrow due to Rh antibody. Pediatrics. 1956;17:37-44.
10.
De BoerIPZeestratenECLoprioreEvan KampILKanhaiHHWaltherFJ.Pediatric outcome in Rhesus hemolytic disease treated with and without intrauterine transfusion. Am J Obstet Gynecol. 2008;198:54.e1-e4. doi:10.1016/j.ajog.2007.05.030
11.
FarrantBBattinMRobertsA.Outcome of infants receiving in-utero transfusions for haemolytic disease. N Z Med J. 2001;114:400-403.
12.
TibladEKublickasMAjneG, et al. Procedure-related complications and perinatal outcome after intrauterine transfusions in red cell alloimmunization in Stockholm. Fetal Diagn Ther. 2011;30:266-273. doi:10.1159/000328683
13.
GarabedianCRakzaTThomasD, et al. Neonatal outcome after fetal anemia managed by intrauterine transfusion. Eur J Pediatr. 2015;174:1535-1539. doi:10.1007/s00431-015-2573-x
14.
OhlsRKWirkusPEChristensenRD.Recombinant erythropoietin as treatment for the late hyporegenerative anemia of Rh hemolytic disease. Pediatrics. 1992;90:678-680.
15.
ScaradavouAInglisSPetersonPDunneJChervenakFBusselJ.Suppression of erythropoiesis by intrauterine transfusions in hemolytic disease of the newborn: use of erythropoietin to treat the late anemia. J Pediatr. 1993;123:279-284. doi:10.1016/s0022-3476(05)81704-4
16.
NicaiseCGireCCashaPd’ErcoleCChauCPalixC.Erythropoietin as treatment for late hyporegenerative anemia in neonates with Rh hemolytic disease after in utero exchange transfusion. Fetal Diagn Ther. 2002;17:22-24. doi:10.1159/000048000
17.
PesslerFHartD.Hyporegenerative anemia associated with Rh hemolytic disease: treatment failure of recombinant erythropoietin. J Pediatr Hematol Oncol. 2002;24:689-693. doi:10.1097/00043426-200211000-00019
18.
AherSMOhlssonA.Late erythropoiesis-stimulating agents to prevent red blood cell transfusion in preterm or low birth weight infants. Cochrane Database Syst Rev. 2020;(1):CD004868. doi:10.1002/14651858.CD004868.pub6
